RT Journal Article
SR Electronic
T1 Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January-March 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21262519
DO 10.1101/2021.09.13.21262519
A1 Meyer, Emily Dorothee
A1 Sandfort, Mirco
A1 Bender, Jennifer
A1 Matysiak-Klose, Dorothea
A1 Dörre, Achim
A1 Bojara, Gerhard
A1 Beyrer, Konrad
A1 Hellenbrand, Wiebke
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.13.21262519.abstract
AB A SARS-CoV-2 Alpha outbreak was detected in a nursing home after residents and staff had completed vaccination with BNT162b. In a retrospective cohort study, we estimated an age-adjusted vaccine effectiveness of 88% [95% confidence interval (95%CI) 41-98%] against hospitalization/death. Ct values at diagnosis were higher with longer intervals since the second vaccination [>21 vs. ≤21 days: 4.82 cycles, 95%CI: 0.06-9.58]. Secondary attack rates were 67% lower in households of vaccinated [2/9 (22.2%)] than unvaccinated infected staff [12/18 (66.7%); p=0.046]. Vaccination reduced the risk of severe outcomes, Ct values and transmission, but not fully. Non-pharmaceutical interventions remain important for vaccinated individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEM and MS are fellows of the German postgraduate training for applied epidemiology (PAE). JB is a fellow of the ECDC Fellowship Programme, supported financially by the European Centre for Disease Prevention and Control (ECDC). This research received no specific grant from any funding agency, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This outbreak investigation was declared exempt of IRB review by Dr Osamah Hamouda, Head of Department of Infectious Disease Epidemiology at the Robert Koch Institute, as it was conducted in accordance to paragraph 4 of the German Protection against Infection Act. Therefore, this investigation was exempt from additional institutional review. (Statement attached as supplementary file)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregated data from a limited version of the German notification system database can be retrieved via SurvStat@RKI 2.0 https://survstat.rki.de/. Detailed data are confidential and protected by German law and are available from the corresponding author upon reasonable request. https://survstat.rki.de/